Tuberc Respir Dis.  2000 Jun;48(6):964-972. 10.4046/trd.2000.48.6.964.

Role of nitric oxide and molsidomine in the management of pulmonary hypertension in Takayasu's arteritis

• Chin JY
• Lee SS
• Lee SS
• Shim TS
• Lim CM
• Koh YS
• Kim WS
• Kim DS
• Kim WD
• Lee SD

• KMID: 2160247
• DOI: http://doi.org/10.4046/trd.2000.48.6.964

Abstract

We report three patients with pulmonary hypertension in Takayasu's arteritis, who showed long-term favorable response, clinically and hemodynamically, to the nitric oxide donor, molsidomine. In these patients, the inhaled nitric oxide was effective in reducing pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR) as was shown in the acute vasodilator response test using the invasive hemodynamic monitoring. Molsidomine (single oral dose of 4 mg) was also effective in reducing PAP and PVR in the acute test, but nifedipine was not. With 4 mg of molsidomine three times daily, their dyspnea, exercise capacity and hemodynamic parameters were improved. These favorable responses have lasted during the 1st and 3rd month follow-up in all patients.

Keyword

Takayasu's arteritis; Pulmonary hypertension; Nitric oxide; Molsidomine

MeSH Terms

Dyspnea
Follow-Up Studies
Hemodynamics
Humans
Hypertension, Pulmonary*
Molsidomine*
Nifedipine
Nitric Oxide*
Pulmonary Artery
Takayasu Arteritis*
Tissue Donors
Vascular Resistance
Molsidomine
Nifedipine
Nitric Oxide